Aleor gets USFDA final approval for Metronidazole gel

Metronidazole gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea.

60

Last Updated on September 8, 2021 by The Health Master

Alembic Pharmaceuticals today announced that its joint venture Aleor Dermaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Metronidazole gel USP, 1%.

In a statement, the company said that the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Metrogel gel, 1%, of Galderma Laboratories.

Metronidazole gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea.

Aleor had previously received tentative approval for this ANDA, the statement said.

Metronidazole gel USP, 1% has an estimated market size of $29 million for twelve months ending June 2021, according to IQVIA, mentioned the statement.

Dr Reddy’s Labs gets USFDA nod for generic Librax capsules

Granules India gets Health Canada nod for drug for Arthritis pain

Sun Pharma gets exclusive right for Winlevi acne cream in US,…

Aurobindo Pharma gets USFDA nod for cancer treatment drug

USFDA approves drug for severe Itching in kidney disease patients

Zydus Cadila gets USFDA nod for Tofacitinib ER Tablets

Police seized assets of Drug peddler: NDPS Act

5 held for smuggling drugs, huge stock of Tramadol recovered

Safety alert against Hepatitis C drug Sofosbuvir: IPC

NLEM: New list of Essential Medicines: 39 new drugs added, 16…

Govt to include ICD as depot to import Drugs under Drugs…

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner